Advertisement
Bioniche purchased the rights and certain assets related to the ENLON(R)product line from Baxter, which discontinued ENLON(R) in February 2008.Bioniche anticipates launching all three codes of ENLON(R) in October 2008.
Advertisement
"We are pleased to reintroduce these products, providing health careprofessionals with access to additional options," said Steve Thornton, CEOBioniche Pharma.
According to IMS data, 2007 sales of ENLON(R) and ENLON-PLUS(R) totaled$2,727,000 and 307,000 units.
About ENLON(R) and ENLON-PLUS(R)
ENLON(R) is recommended for the differential diagnosis of myastheniagravis and as an adjunct in the evaluation of treatment requirements in thisdisease. It may also be used for evaluating emergency treatment in myastheniccrises. Because of its brief duration of action, it is not recommended formaintenance therapy in myasthenia gravis. ENLON(R) is also useful whenever acurare antagonist is needed to reverse the neuromuscular block produced bycurare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It isnot effective against decamethonium bromide and succinylcholine chloride. Itmay be used adjunctively in the treatment of respiratory depression caused bycurare overdosage.
ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)Injection is recommended as a reversal agent or antagonist of nondepolarizingneuromuscular blocking agents. It is not effective against depolarizingneuromuscular blocking agents. It is also useful if used adjunctively in thetreatment of respiratory depression caused by curare overdosage.
About Bioniche Pharma:
Bioniche Pharma is a global manufacturer of injectable pharmaceuticalproducts serving a variety of niche markets, with expertise in injectablehyaluronic acid products for use in orthopedics, rheumatology, urology anddermatology. The company's growth is fueled by an internal developmentpipeline and an aggressive acquisition strategy for products. Bioniche Pharmawas acquired in February 2006 by RoundTable Healthcare Partners, a privateequity firm based in Lake Forest, Illinois. More information about BionichePharma can be found at http://www.bionichepharma.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)-- ENLON(R) (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial -- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection 5 mL ampule -- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection, 15 mL Multi-dose Vial
SOURCE Bioniche Pharma
